Clinical trials · Raleigh–Durham, NC
Cancer clinical trials in Raleigh–Durham
We’re tracking 418 recruiting cancer studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Durham, North CarolinaAges 18 years+ - NCT06646276RecruitingPhase 3
New drug combo vs standard care for first-line extensive-stage small cell lung cancer
This trial tests a new combination of drugs (BMS-986489 with chemotherapy) against the current standard treatment (atezolizumab with chemotherapy) for people who have just been diagnosed with extensive-stage small cell lung cancer. It aims to see which approach works better and is safer.
Durham, North CarolinaAges 18 years+ - NCT06252649RecruitingPhase 3
Study of new drug combo for KRAS G12C colorectal cancer
This trial tests a new combination of drugs (sotorasib, panitumumab, and FOLFIRI) against the standard treatment for colorectal cancer that has spread. It's for people whose tumor has a specific KRAS G12C mutation and who have not had chemotherapy before for advanced disease.
Durham, North CarolinaAges 18 years+ - NCT06525220RecruitingPhase 3
New drug combo vs. standard for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
Durham, North CarolinaAges 18 years+ - NCT07216456Recruiting
Vaginal dilator therapy after pelvic radiation
This trial tests a program to help women use vaginal dilators after finishing pelvic radiation for cancers like cervical or anal cancer. It aims to improve vaginal health and quality of life.
Durham, North CarolinaAges 18 years+ - NCT07235293RecruitingPhase 2
Testing a new drug combo for advanced colorectal cancer
This trial tests a new combination of two drugs (DSP107 and atezolizumab) compared to another drug (fruquintinib) for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to find a more effective treatment option.
Durham, North CarolinaAges 18 years+ - NCT06141993Recruiting
Study of blood markers in hormone therapy resistance for prostate cancer
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
Durham, North CarolinaAges 18 years+ - NCT06840886RecruitingPhase 1
Testing a new drug for advanced solid tumors
This study tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can help shrink tumors.
Durham, North CarolinaAges 18 years+ - NCT05828069RecruitingPhase 2
Tovorafenib for young people with worsening Langerhans cell histiocytosis
This Phase 2 trial tests tovorafenib (DAY101) to treat children and young people whose Langerhans cell histiocytosis (LCH) is getting worse, came back, or did not respond to prior treatment. It may help by targeting certain gene changes found in the LCH.
Durham, North CarolinaAges 6 months–22 years - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Durham, North CarolinaAges 18 years+ - NCT06532773RecruitingDurham, North CarolinaAges 18 years+
- NCT07426952Recruiting
Weight management support for breast cancer survivors
This study tests a weight management program for breast cancer survivors who live in rural areas. The program aims to help you manage weight and improve symptoms.
Durham, North CarolinaAges 18 years+ - NCT07300995Recruiting
Pain coping skills for older women with breast cancer
This study tests a behavioral program to help older women with breast cancer learn skills to cope with pain. The program is done through video or phone sessions.
Durham, North CarolinaAges 55 years+ - NCT05974150Recruiting
Remote symptom monitoring for several blood and cancer types
This study checks how well remote (at-home) symptom check-ins work for people with certain cancers. It may help patients and clinicians spot problems earlier and improve day-to-day care during treatment and beyond.
Durham, North CarolinaAges 18 years+ - NCT07491497RecruitingPhase 1/Phase 2
Study of TRI-611 for ALK-positive lung cancer
This trial tests a new investigational drug called TRI-611 for people with ALK-positive non-small cell lung cancer. It is designed for people who have already tried other ALK-targeted medicines, especially lorlatinib, and whose cancer may have stopped responding to them.
Durham, North CarolinaAges 18 years+ - NCT07321652RecruitingPhase 3
Sonrotoclax plus zanubrutinib for untreated CLL or SLL
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Durham, North CarolinaAges 65 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Durham, North CarolinaAges 18 years+ - NCT05977621Recruiting
Ultrasound imaging to guide radiation needle placement
This trial tests a guidance technique that uses ultrasound images matched to MRI (a real-time “map”) to help track the needle position during treatment for cervical or uterine cancer. It may help make radiation treatments more precise for people who are getting curative-intent radiation with brachytherapy.
Durham, North CarolinaAges 18–90 - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Durham, North CarolinaAges 18 years+ - NCT07097142RecruitingPhase 3
Shorter radiation for bladder cancer with chemo
This trial tests if a shorter course of radiation therapy works as well as the usual longer course for people with bladder cancer who are also receiving standard chemotherapy. The goal is to see if shorter treatment can reduce side effects while still being effective.
Durham, North CarolinaAges 18 years+ - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Durham, North CarolinaAges 18–59 - NCT04486352RecruitingPhase 1/Phase 2
Targeted therapy trial for recurrent or persistent endometrial cancer
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
Durham, North CarolinaAges 18 years+ - NCT06901531RecruitingPhase 3
Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Durham, North CarolinaAges 18 years+ - NCT06555588Recruiting
Supportive talk therapy for advanced cancer symptoms
This study tests a supportive talk therapy program (called Engage) delivered via video calls. It aims to help people with advanced cancer manage tough symptoms like pain, fatigue, and distress and improve daily functioning.
Durham, North CarolinaAges 18 years+
Hear when a new Cancer trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting cancer studies listed above.
- Duke University Medical Center · 9 studies
- Duke Cancer Institute · 6 studies
- Duke Cancer Center · 5 studies
- UNC Lineberger Comprehensive Cancer Center · 2 studies
- University of North Carolina at Chapel Hill · 2 studies
- 2400 Pratt Street
- Duke
- Duke University
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in North Carolina.
Common questions
- Are there cancer clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 418 recruiting cancer studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.